Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors

Cancer Gene Therapy

Volumn 6, Issue 3, 1999, Pages 209-219

  Stackhouse, Murray A ^a,d   Buchsbaum, Donald J ^a   Kancharla, Sreekanth R ^a   Grizzle, William E ^b   Grimes, Christie ^a   Laffoon, Kim ^a   Pederson, Lee C ^c   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

^d The University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus; DF3; erbB 2; Gastrin releasing peptide receptor; Genetic radioisotope targeting strategy; Transcriptional targeting

Indexed keywords

BOMBESIN RECEPTOR; CA 15-3 ANTIGEN; DF3 BREAST CARCINOMA ASSOCIATED ANTIGEN; DF3 BREAST-CARCINOMA-ASSOCIATED ANTIGEN; KERATIN; ONCOPROTEIN; TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; FIBROBLAST; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MOUSE; PROMOTER REGION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; KERATINS; MICE; MODELS, GENETIC; ONCOGENE PROTEINS V-ERBB; PROMOTER REGIONS (GENETICS); RECEPTORS, BOMBESIN; TUMOR CELLS, CULTURED;

EID: 0033129304     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700049     Document Type: Article

References (49)

1. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, Fla: CRC Press; 1995:115-140.
2. Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J Clin. 1994;44:43-64.
3. Jurcic JG, Scheinberg DA. Radioimmunotherapy of hematological cancer: problems and progress. Clin Cancer Res. 1995;1:1439-1446.
4. Knox SJ. Radioimmunotherapy of non-Hodgkin's lymphoma. Semin Radiat Oncol. 1995;5:331-341.
5. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol. 1996;14:1383-1400.
6. Raben D, Buchsbaum DJ, Khazaeli MB, et al. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther. 1996;3:567-580.
7. Hand PH, Robbins PF, Salgaller ML, Poole DJ, Schlom J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother. 1993;36:65-75.
8. Falck-Pedersen E, Heinflink M, Alvira M, Nussenzveig DR, Gershengorn MC. Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. Mol Pharmacol. 1994;45:684-689.
9. Hinuma S, Hosoya M, Ogi K, et al. Molecular cloning and functional expression of a human thyrotropin-releasing hormone (TRH) receptor gene. Biochim Biophys Acta. 1994;1219:251-259.
10. Buchsbaum DJ, Raben D, Stackhouse MA, et al. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther. 1996;3:1042-1068.
11. Raben D, Buchsbaum DJ, Khazaeli MB, et al. Strategies to augment radioimmunotherapy via genetic induction of receptors for radioligand binding. Cancer Gene Ther. 1995; 2:330.
12. 2 in ovarian carcinoma induced to express the gastrin-releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med. 1997;38:1221-1229.
13. Rosenfeld ME, Rogers BE, Khazaeli MB, et al. Adenoviral mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin Cancer Res. 1997;3:1187-1194.
14. Hoffman TJ, Sieckman GL, Volkert WA. Targeting small cell lung cancer using iodinated peptide analogs. J Label Compd Radiophann. 1995;37:321-323.
15. Hoffman TJ, Sieckman GL, Volkert WA. Iodinated bombesin analogues: effect of N-terminal vs side chain iodine attachment on BBN/GRP receptor binding. J Nucl Med. 1996;37:185P.
16. Ning L, Hoffman TJ, Sieckman GL, et al. In-vitro and in-vivo characterization of a Rh-105-tetrathiamacrocycle conjugate of a bombesin analogue. J Nucl Med. 1996;37: 61P.
17. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994;1:51-64.
18. Trapnell B, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol. 1994;5:617-625.
19. Overturf K, al-Dhalimy M, Ou CN, et al. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther. 1997;8:513-521.
20. Garver RI, Jr. Transcriptional targeting for cancer gene therapy: a review. In: Sobol RE, Scanlon KJ, eds. The Internet Book of Gene Therapy-Cancer Therapeutics. Stamford, Conn: Appleton & Lange; 1995:195-203.
21. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
22. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol. 1993;4:19-26.
23. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J. 1993; 12:2369-2375.
24. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1994;1:170-175.
25. Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR. Expression of MUC1, MUC2, MUC3, and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer. 1994;57:198-203.
26. Devine PL, Birrell GW, Whitehead RH, et al. Expression of MUC1 and MUC2 mucins by human tumor cell lines. Tumor Biol. 1992;13:268-277.
27. Yamashita K, Yonezawa S, Tanaka S, et al. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer. 1993;55:82-91.
28. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641-651.
29. Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor-Papadimitriou J. Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem. 1993;268:9917-9926.
30. Kovarik A, Lu PJ, Peat N, Morris J, Taylor-Papadimitriou J. Two GC boxes (SP1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter. J Biol Chem. 1996;271:18140-18147.
31. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA. 1993;90:282-286.
32. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 1994;54:5408-5413.
33. Chen L, Pulsipher M, Chen D, et al. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996;98:2539-2548.
34. Becker TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43:161-189.
35. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walaszek Z, eds. John Walker's Methods in Molecular Medicine-Tumor Marker Protocols. Totowa, NJ: Humana Press; 1998:143-160.
36. Grizzle WE, Myers RB, Manne U, et al. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walaszek Z, eds. John Walker's Methods in Molecular Medicine-Tumor Marker Protocols. Totowa, NJ: Humana Press,; 1998:161-179.
37. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol. 1995;153: 1572-1574.
38. Kury FD, Schneeberger C, Sliutz G, et al. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol-free method for nucleic acid isolation. Oncogene. 1990;5:1403-1408.
39. Ring CJA, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral, and plasmid vectors containing the ERBB2 promoter. Gene Ther. 1996;3:1094-1103.
40. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 1995;6:1055-1063.
41. Arbuthnot PB, Bralet M-P, Le Jossic C, et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996;7: 1503-1514.
42. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56:5638-5646.
43. Kanai F, Lan K-H, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma byadenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.
44. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
45. Tanaka T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996;56:1341-1345.
46. Chen L, Chen D, Manome Y, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest. 1995;96:2775-2782.
47. Wills KN, Huang WM, Harris MP, et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;3:191-197.
48. Imler JL, Dupuit F, Chartier C, et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther. 1996;3:49-58.
49. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther. 1997;8:403-410.